title: In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
abstract: BACKGROUND
  DNA-based vaccines have been safe but weakly immunogenic in humans to date.
  
  
  RESULTS
  We sought to determine the safety, tolerability, and immunogenicity of ADVAX, a multigenic HIV-1 DNA vaccine candidate, injected intramuscularly by in vivo electroporation (EP) in a Phase-1, double-blind, randomized placebo-controlled trial in healthy volunteers. Eight volunteers each received 0.2 mg, 1 mg, or 4 mg ADVAX or saline placebo via EP, or 4 mg ADVAX via standard intramuscular injection at weeks 0 and 8. A third vaccination was administered to eleven volunteers at week 36. EP was safe, well-tolerated and considered acceptable for a prophylactic vaccine. EP delivery of ADVAX increased the magnitude of HIV-1-specific cell mediated immunity by up to 70-fold over IM injection, as measured by gamma interferon ELISpot. The number of antigens to which the response was detected improved with EP and increasing dosage. Intracellular cytokine staining analysis of ELISpot responders revealed both CD4+ and CD8+ T cell responses, with co-secretion of multiple cytokines.
  
  
  CONCLUSIONS
  This is the first demonstration in healthy volunteers that EP is safe, tolerable, and effective in improving the magnitude, breadth and durability of cellular immune responses to a DNA vaccine candidate.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT00545987.
authors: Aaron Diamond AIDS Research Center, New York, New York, United States of America. svasan@adarc.org
authors: Sandhya
authors: S
authors: Vasan
authors: Arlene
authors: A
authors: Hurley
authors: Sarah J
authors: SJ
authors: Schlesinger
authors: Drew
authors: D
authors: Hannaman
authors: David F
authors: DF
authors: Gardiner
authors: Daniel P
authors: DP
authors: Dugin
authors: Mar
authors: M
authors: Boente-Carrera
authors: Roselle
authors: R
authors: Vittorino
authors: Marina
authors: M
authors: Caskey
authors: Johanne
authors: J
authors: Andersen
authors: Yaoxing
authors: Y
authors: Huang
authors: Josephine H
authors: JH
authors: Cox
authors: Tony
authors: T
authors: Tarragona-Fiol
authors: Dilbinder K
authors: DK
authors: Gill
authors: Hannah
authors: H
authors: Cheeseman
authors: Lorna
authors: L
authors: Clark
authors: Len
authors: L
authors: Dally
authors: Carol
authors: C
authors: Smith
authors: Claudia
authors: C
authors: Schmidt
authors: Harriet H
authors: HH
authors: Park
authors: Jakub T
authors: JT
authors: Kopycinski
authors: Jill
authors: J
authors: Gilmour
authors: Patricia
authors: P
authors: Fast
authors: Robert
authors: R
authors: Bernard
authors: David D
authors: DD
authors: Ho
references: Nat Rev Genet. 2008 Oct;9(10):776-88
references: 18781156
references: Intervirology. 2000;43(4-6):273-81
references: 11251382
references: Vaccine. 2008 May 23;26(22):2788-95
references: 18440674
references: Vaccine. 2010 Jan 22;28(4):950-7
references: 19925902
references: Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13538-43
references: 18765801
references: Vaccine. 2008 Jun 13;26(25):3112-20
references: 18430495
references: Vaccine. 2007 May 16;25(20):4085-92
references: 17391815
references: Vaccine. 2006 May 22;24(21):4490-3
references: 16140436
references: J Virol. 2006 May;80(10):4717-28
references: 16641265
references: Vaccine. 2008 Jun 13;26(25):3162-74
references: 18502003
references: Hum Gene Ther. 2009 Nov;20(11):1269-78
references: 19619001
references: Vaccine. 2010 Jan 22;28(4):1056-61
references: 19896452
references: Science. 1998 Oct 16;282(5388):476-80
references: 9774275
references: J Virol. 2005 May;79(10):6516-22
references: 15858035
references: Vaccine. 2007 Jun 21;25(26):4967-82
references: 17335943
references: Transpl Int. 2009 Nov;22(11):1041-50
references: 19624493
references: Vaccine. 2003 Nov 7;21(31):4604-8
references: 14575774
references: PLoS One. 2010 Jan 25;5(1):e8617
references: 20111582
references: Eur J Surg Oncol. 2008 Feb;34(2):232-40
references: 17614247
references: Vaccine. 2007 Feb 26;25(10):1814-23
references: 17240007
references: J Biotechnol. 2004 May 13;110(1):1-10
references: 15099900
references: Vaccine. 2007 Sep 4;25(36):6635-45
references: 17669562
references: Nat Rev Cancer. 2008 Feb;8(2):108-20
references: 18219306
references: Vaccine. 2008 Jul 23;26(31):3947-57
references: 18724414
references: Front Biosci. 2007 Jan 01;12:2330-43
references: 17127243
references: J Virol. 2007 May;81(10):5257-69
references: 17329330
references: J Virol. 2008 Jun;82(11):5643-9
references: 18353952
references: Gene Ther. 1999 Apr;6(4):508-14
references: 10476210
references: Vaccine. 2006 May 22;24(21):4565-8
references: 16154246
references: J Exp Med. 2008 Jan 21;205(1):63-77
references: 18195071
references: Science. 1993 Mar 19;259(5102):1745-9
references: 8456302
references: J Infect Dis. 2006 Dec 15;194(12):1650-60
references: 17109336
references: Science. 2006 Jun 9;312(5779):1530-3
references: 16763152
references: Blood. 2006 Jun 15;107(12):4781-9
references: 16467198
references: Clin Diagn Lab Immunol. 2004 Mar;11(2):351-7
references: 15013987
references: J Immunol. 2005 Jul 15;175(2):633-9
references: 16002657
references: J Immunol. 2000 May 1;164(9):4635-40
references: 10779767
references: Vaccine. 2002 Sep 10;20(27-28):3399-3408
references: 12213410
references: Nat Med. 2003 Jun;9(6):729-35
references: 12766765
references: Hum Vaccin. 2006 Mar-Apr;2(2):45-53
references: 17012886
references: J Infect Dis. 2010 Jan 1;201(1):132-41
references: 19929694
references: Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14646-52
references: 15292504
references: Vaccine. 2008 Sep 19;26(40):5223-9
references: 18468743
references: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):403-11
references: 18209683